WO2005066133A2 - NOVEL PROCESS FOR PREPARATION OF 10-OXO-10, 11-DIHYDRO-5H-DIBENZ [b,f]AZEPINE-5-CARBOXAMIDE (OXCARBAZEPINE) VIA INTERMEDIATE, 10-METHOXY-5H-DIBENZ[b,f] AZEPINE-5-CARBONYLCHLORIDE - Google Patents

NOVEL PROCESS FOR PREPARATION OF 10-OXO-10, 11-DIHYDRO-5H-DIBENZ [b,f]AZEPINE-5-CARBOXAMIDE (OXCARBAZEPINE) VIA INTERMEDIATE, 10-METHOXY-5H-DIBENZ[b,f] AZEPINE-5-CARBONYLCHLORIDE Download PDF

Info

Publication number
WO2005066133A2
WO2005066133A2 PCT/IN2004/000322 IN2004000322W WO2005066133A2 WO 2005066133 A2 WO2005066133 A2 WO 2005066133A2 IN 2004000322 W IN2004000322 W IN 2004000322W WO 2005066133 A2 WO2005066133 A2 WO 2005066133A2
Authority
WO
WIPO (PCT)
Prior art keywords
dibenz
azepine
methoxy
novel process
oxcarbazepine
Prior art date
Application number
PCT/IN2004/000322
Other languages
French (fr)
Other versions
WO2005066133A3 (en
Inventor
Chandrashekar Parenky
Rohit Chaturvedi
Original Assignee
Amoli Organics Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amoli Organics Ltd. filed Critical Amoli Organics Ltd.
Priority to EP04820974A priority Critical patent/EP1678140A2/en
Priority to US10/576,546 priority patent/US20070032647A1/en
Publication of WO2005066133A2 publication Critical patent/WO2005066133A2/en
Publication of WO2005066133A3 publication Critical patent/WO2005066133A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/18—Dibenzazepines; Hydrogenated dibenzazepines
    • C07D223/22—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines

Definitions

  • the present invention relates to an improved process for preparation of 10-methoxy- 5H-dibenz[b,fjazepine-5-carbonyl chloride from 10-methoxy-5H-dibenz[b,f]azepine (10-methoxy iminostilbene) without the use of phosgene and its further conversion to 10-oxo-IO, 11 -dihydro-5H-dibenz[b,f]azepine-5-carboxamide (oxcarbazepine) without the use of strong mineral acids.
  • Oxcarbazepine is an anticonvulsant drug used as an anti-epileptical agent in treatment of AIDS-related neural disorders and for treatment of Parkinson's disease
  • US Patent 3462775 describes the preparation of oxcarbazepine from 10-methoxy iminostilbene by phosgenation in toluene, followed by amidation (ethanol and ammonia) and hydrolysis in acidic medium to get e desired product (Scheme 1 ).
  • the phosgenation is carried out at relatively high temperatures of around 95°C and the hydrochloric acid produced leads to the formation of undesirable impurities.
  • the process uses phosgene gas, which is toxic and hazardous requiring extreme precaution making this process commercially unattractive.
  • Canadian Patent 112 241 describes an alternate preparation of oxcarbazepine from the catalysed re-arrangement of 10,11-epoxycarbamazepine, prepared from carbamazepine by reaction with m-chloroperbenzoic acid (CPBA) (Scheme-2). Starting with Carbamazepine, which is an expensive raw material, the conversion to its epoxide is poor in quality and yield.
  • CPBA m-chloroperbenzoic acid
  • EP Patent Application 028028 discloses a process involving nitration of 5- cyanoiminostilbene followed by reduction and hydrolysis (Scheme-3).
  • Scheme 3 discloses a process involving nitration of 5- cyanoiminostilbene followed by reduction and hydrolysis.
  • the drawback of the process is in the preparation of the 5- cyanoiminostilbene itself, which can be made from iminostilbene and cyanogen chloride. The latter is also toxic, hazardous and difficult to handle.
  • Swiss Patent No. 642 950 suggests hydrolysis of the 10-chloro-5H-dibenz [ b,f ] azepin-5-carboxamide using concentrated sulphuric acid to form the oxcarbazepine. However the yields are poor.
  • the main object of the invention is to provide a cost effective, safe and high yielding process for the production of 10-methoxy-5H-dibenz[b,f]azepine-5-carbonyl chloride, from 10-methoxy-5H-dibenz [b,f]azepine (10-methoxy iminostilbene) without the use of phosgene gas as is practiced in the prior art an important intermediate for the synthesis of 10-oxo-10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide
  • Another object of the invention is o develop a process thaf can be carrie out at relatively lower temperatures to avoid the formation of any undesirable impurities.
  • Yet another object of the invention is to provide a cost effective process using easily available raw materials.
  • Yet another object of the invention is to provide a process for the conversion of the intermediate 10-methoxy-5H-dibenz[b,f]azepine-5-carboxamide to 10-oxo-IO, 11- dihydro-5H-dibenz[b,f]azepine-5-carboxamide (oxcarbazepine) using mild reagents such as methane sulphonic acid, para toluene sulphonic acid, Lewis acids,_caiionic resins, etc.
  • mild reagents such as methane sulphonic acid, para toluene sulphonic acid, Lewis acids,_caiionic resins, etc.
  • reaction (scheme 4) comprises steps
  • 10-Methoxyiminostilbene is dissolved in a solvent and cooled below 10°C and bis- (trichloromethyl) carbonate (BTC) is added.
  • BTC bis- (trichloromethyl) carbonate
  • An organic base is slowly added to the above solution over a period ranging fro-3-24-hours maintainiRg-the ; temperature -below- 10°C till the reaction goes to completion.
  • the reaction mixture- is allowed to -warm - up to- around room temperature- and maintained at this temperature till the completion of the reaction as monitored by TLC/HPLC.
  • the reaction mixture is quenched in water and the layers are allowed to separate.
  • the solvent used in the carbonyl chloride preparation step may be selected from chlorinated aliphatic hydrocarbons such as methylene dichloride, chloroform, ethylene dichloride, 1 , 1 ,1 ,-trichloroethane, trichloroethylene etc. or aromatic hydrocarbon solvent such as toluene, xylene, chlorobenzene, etc. or aprotic solvents including Dimethyl formamide, dimethyl acetamide,- N-methyl pyrrolidine and acetonitrile.
  • the organic base used in this step is selected from aliphatic/ aromatic tertiary arnines such as triethyl amine/ diethyl aniline, pyridine, picoline etc.
  • initial addition of the base may be followed by the addition of BTC.
  • the time of the addition of base ranges from .3 -8 hrs, the temperature at which the base is added may range upto 30°C preferably below 10°C and most preferably from 0° to + ⁇ °C.
  • the reaction period may vary from about 3 hours to about 10 hours.
  • the molar ratio of 10-methoxy iminostilbene to BTC is 1 :0.34-0.5.
  • the molar ratio of 10-methoxy iminostilbene verses the base is 1: 1-1.5.
  • the solvents preferred in the amidation reaction are selected from solvents like acetone, methyl cellosolve, methanol, ethanol, isopropyl alcohol, dimethyl formamide, dimethlacetamide, N-methyl pyrrolidone or aromatic.solvents like toluene, xylene etc.
  • the solvent used in the final oxo preparation step ay be selected from chlorinated aliphatic hydrocarbons such as methylene dichloride, chloroform, ethylene dichloride, 1 , 1 ,1,-trichloroethane, trichloroethylene etc or aromatic hydrocarbon solvent such as toluene, xylene, chlorobenzene, etc. or aprotic solvents including dimethyl formamide, dimethyl acetamide, N-methyl pyirrolidine and acetonitrile.
  • chlorinated aliphatic hydrocarbons such as methylene dichloride, chloroform, ethylene dichloride, 1 , 1 ,1,-trichloroethane, trichloroethylene etc or aromatic hydrocarbon solvent such as toluene, xylene, chlorobenzene, etc. or aprotic solvents including dimethyl formamide, dimethyl acetamide, N-methyl pyirrolidine and acetonitrile.
  • the Lewis acids used in this are selected from! cationic resins, para- toluene sulfonic acid, aluminium chloride, etc.
  • the temperature at which the reaction may be carried out may vary from 25 to 80°C, preferably between 50 to 70°C
  • the present invention obviates the use of phosgene gas in the preparation of 10- methoxy ⁇ -dibenz[b,f]azepine-£ carbonyl chloride from 10 ⁇ methoxy-5H- dibe ⁇ ,f]azepine (10-methgxy iminostilbene).
  • the invention provide a process for the conversion of the intermediate 10-methoxy-5H-dibenz[b,f]azepine-5- carboxami ⁇ e to 10-oxo-10,11-dihydro-5H-dibenz [b,f] azepine-5-carboxamide (oxcarbazepine) without the use harsh conditions and strong mineral acids thereby obtaining high quality oxcarbazepine in a cost effective manner from easily available raw materials.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Novel process for preparation of 10-oxo-10, 11-dihydro-SH-dibenz[b,f] azepine-5­-carboxamide (oxcarbazepine) via intermediate 10-methoxy-5H­-dibenz [b,f] azepine -5 carbonyl, chloride; comprising the steps: a) Preparation of an intermediate 10-methoxy-5H-dibenz [b,f] azepine -5 carbonyl, chloride from 10-methoxyiminostillbene using bis (trichloromethyl) carbonate (BTC) with organic base such as aliphatic or aromatic tertiary amines in organic solvent b) Conversion of the intermediate to 10-methoxy-5H-dlbenz[b,f] azepine -5-­ carboxamide using ammonia in organic solvent c) Formation of oxcarbazepine from step(b) using Lewis acid in an organic solvent at a temperature between 25°C - 80°C, preferably at 50°C to 70°C d) Isolation of oxcarbazepine.

Description

TITLE :
Novel process for preparation of 10-oxo-IO, 11-dihydro-5H-dibenz [b,f}azepine-5- carboxamide (oxcarbazepine) via intermediate, 10-methoxy-5H-dibenz[b,f] azepine-5-carbonylchloride.
Field of the Invention
The present invention relates to an improved process for preparation of 10-methoxy- 5H-dibenz[b,fjazepine-5-carbonyl chloride from 10-methoxy-5H-dibenz[b,f]azepine (10-methoxy iminostilbene) without the use of phosgene and its further conversion to 10-oxo-IO, 11 -dihydro-5H-dibenz[b,f]azepine-5-carboxamide (oxcarbazepine) without the use of strong mineral acids.
Background and prior art
Oxcarbazepine is an anticonvulsant drug used as an anti-epileptical agent in treatment of AIDS-related neural disorders and for treatment of Parkinson's disease
Several processes for preparing Oxcarbazepine have been reported.
US Patent 3462775 describes the preparation of oxcarbazepine from 10-methoxy iminostilbene by phosgenation in toluene, followed by amidation (ethanol and ammonia) and hydrolysis in acidic medium to get e desired product (Scheme 1 ). The phosgenation is carried out at relatively high temperatures of around 95°C and the hydrochloric acid produced leads to the formation of undesirable impurities. The process uses phosgene gas, which is toxic and hazardous requiring extreme precaution making this process commercially unattractive.
Scheme 1
Figure imgf000003_0001
Oxcarbazepine
Canadian Patent 112 241 describes an alternate preparation of oxcarbazepine from the catalysed re-arrangement of 10,11-epoxycarbamazepine, prepared from carbamazepine by reaction with m-chloroperbenzoic acid (CPBA) (Scheme-2). Starting with Carbamazepine, which is an expensive raw material, the conversion to its epoxide is poor in quality and yield.
Scheme 2
Figure imgf000003_0002
Carbamazepine mide
Figure imgf000003_0003
xcar azep ne
EP Patent Application 028028, discloses a process involving nitration of 5- cyanoiminostilbene followed by reduction and hydrolysis (Scheme-3). However, the drawback of the process is in the preparation of the 5- cyanoiminostilbene itself, which can be made from iminostilbene and cyanogen chloride. The latter is also toxic, hazardous and difficult to handle. Scheme 3
Figure imgf000004_0001
Iminostilbine
Hydrolysis
Figure imgf000004_0003
Figure imgf000004_0002
10 Amino 5 cyano 5 II di benz [b,fjazepiπ Oxcarbazepine
Swiss Patent No. 642 950 suggests hydrolysis of the 10-chloro-5H-dibenz [ b,f ] azepin-5-carboxamide using concentrated sulphuric acid to form the oxcarbazepine. However the yields are poor.
Further it may be noted that in all the processes disclosed in the prior art discussed above (Scheme 1 and Scheme 3) and US Patent 5808058, EP Application 1 302 464 A1 and PCT Publication WO 01/56992A2, the conversion of 10-methoxy-5H- dibenz[b,f]azepine-5-carboxamide to 10-oxo-10,11-dihydro-5H-dibenz[b,f]azepine-5- carboxamide (oxcarbazepine) is effected using strong mineral acids or mixture of mineral acids and acetic acid in aqueous medium. This leads to degradation of oxcarbazepine
Methods described in the prior art have severe limitations in terms of poor quality and yields and also in some cases with the use of hazardous materials such as phosgene that need extreme care during usage making them commercially unattractive. Moreover the HCI formed during the course of the reaction and the relatively higher temperatures used leads to formation of undesired impurities.
There is a long standing need in the industry to provide cost effective, safe and easy operative processes for the production of 10-methoxy-5H-dibenz[b,f]azepine-5- carbonyl chloride from 10-methoxy-5H-dibenz[b,f]azepine (10-methoxy iminostilbene) without the use of phosgene and its further conversion to 10-oxo-10,11-dihydro-5H- dibenz[b,fjazepine-5-carboxamide (oxcarbazepine) without trie use of mineral acids.
Summary of the invention
The main object of the invention is to provide a cost effective, safe and high yielding process for the production of 10-methoxy-5H-dibenz[b,f]azepine-5-carbonyl chloride, from 10-methoxy-5H-dibenz [b,f]azepine (10-methoxy iminostilbene) without the use of phosgene gas as is practiced in the prior art an important intermediate for the synthesis of 10-oxo-10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide
(oxcarbazepine). It is further an object of the invention to provide a process for the conversion of the intermediate 10-methoxy-5H- dibenz[b,f]azepine-5-carboxamide to 10-oxo-10,11-dihydro-5H-dibenz [b,f] azepine-5- carboxamide (oxcarbazepine) without the use of mineral acids.
Another object of the invention is o develop a process thaf can be carrie out at relatively lower temperatures to avoid the formation of any undesirable impurities.
Yet another object of the invention is to provide a cost effective process using easily available raw materials.
Yet another object of the invention is to provide a process for the conversion of the intermediate 10-methoxy-5H-dibenz[b,f]azepine-5-carboxamide to 10-oxo-IO, 11- dihydro-5H-dibenz[b,f]azepine-5-carboxamide (oxcarbazepine) using mild reagents such as methane sulphonic acid, para toluene sulphonic acid, Lewis acids,_caiionic resins, etc.
Detailed description of invention Scheme 4
Figure imgf000006_0001
Oxcarbazepine
Thus in accordance of this invention the reaction (scheme 4) comprises steps
• Preparation of intermediate 10-Methoxy-5H-dibenz [b,f] azepine-5-carbonyl chloride from 10- methoxyiminostilbine using bis-(trichloromethyl) carbonate (BTC) or triphosgene and an appropriate base in the presence of an organic solvent.
• Conversion of 10-Methoxy-5H-dibenz [b,f]azepine-5-carbonyl chloride to. 10- Methoxy-5H-dibenz [b, f] azepine-5-carboxamide using ammonia in a suitable organic solvent
• Formation of oxcarbazepine from 1 0-Methoxy-5H-dibenz [b, f] azepine-5- carboxamide using Lewis acids in appropriate organic solvent.
10-Methoxyiminostilbene is dissolved in a solvent and cooled below 10°C and bis- (trichloromethyl) carbonate (BTC) is added. An organic base is slowly added to the above solution over a period ranging fro-3-24-hours maintainiRg-the; temperature -below- 10°C till the reaction goes to completion. Optionally on completion of the base addition the reaction mixture- is allowed to -warm - up to- around room temperature- and maintained at this temperature till the completion of the reaction as monitored by TLC/HPLC. On completion of the reaction, the reaction mixture is quenched in water and the layers are allowed to separate. The organic layer is separated and distilled to obtain crude 10-methoxy-5H-dibenz [b,f] azepine-5-carbonyl chloride which is purified using an organic solvent. In the subsequent step 10-Methoxy-5H-dibenz (b,f) azepine-5-carbonyl chloride is refluxed in an aprotic solvent and ammonia gas is purged till the reaction goes to completion. The solvent is distilled and water is added, cooled to room temperature to isolate the 10-Methoxy-5H-dibenz [b ,f] azepine-5-carboxamide.
10-Methoxy-5H-dibenz [b, f] azepine-5-carboxamide is stirred in an organic solvent in the presence of a Lewis acid at temperature upto 80°C depending on the solvent used. On completion of the reaction the reaction mixture is cooled to room temperature and the crude oxcarbazepine is separated and purified.
The solvent used in the carbonyl chloride preparation step may be selected from chlorinated aliphatic hydrocarbons such as methylene dichloride, chloroform, ethylene dichloride, 1 , 1 ,1 ,-trichloroethane, trichloroethylene etc. or aromatic hydrocarbon solvent such as toluene, xylene, chlorobenzene, etc. or aprotic solvents including Dimethyl formamide, dimethyl acetamide,- N-methyl pyrrolidine and acetonitrile.- The organic base used in this step is selected from aliphatic/ aromatic tertiary arnines such as triethyl amine/ diethyl aniline, pyridine, picoline etc.
In an embodiment of the process initial addition of the base may be followed by the addition of BTC.
The time of the addition of base ranges from .3 -8 hrs, the temperature at which the base is added may range upto 30°C preferably below 10°C and most preferably from 0° to +§°C. The reaction period may vary from about 3 hours to about 10 hours. The molar ratio of 10-methoxy iminostilbene to BTC is 1 :0.34-0.5. The molar ratio of 10-methoxy iminostilbene verses the base is 1: 1-1.5.
The solvents preferred in the amidation reaction are selected from solvents like acetone, methyl cellosolve, methanol, ethanol, isopropyl alcohol, dimethyl formamide, dimethlacetamide, N-methyl pyrrolidone or aromatic.solvents like toluene, xylene etc.
The solvent used in the final oxo preparation step ay be selected from chlorinated aliphatic hydrocarbons such as methylene dichloride, chloroform, ethylene dichloride, 1 , 1 ,1,-trichloroethane, trichloroethylene etc or aromatic hydrocarbon solvent such as toluene, xylene, chlorobenzene, etc. or aprotic solvents including dimethyl formamide, dimethyl acetamide, N-methyl pyirrolidine and acetonitrile.
The Lewis acids used in this are selected from! cationic resins, para- toluene sulfonic acid, aluminium chloride, etc.
The temperature at which the reaction may be carried out may vary from 25 to 80°C, preferably between 50 to 70°C
The invention is now illustrated with a few non-limiting examples.
Example 1
Step 1. Preparation of 10-Methoxy-5H-dibenz [b,f] azepine-5-carbonyl chloride
100 gms of 10 Methoxy iminostilbene is dissolved in 300 ml chloroform & cooled to 0 °C Bis (trichloro methyl) carbonate (BTC) 65 gms is added. 67 gms of triethy! amine (TEA) in 100 ml chloroform is added slowly over a period of δ hour & maintaining the temperature 0 - 5°C. Temperature is then increased to 25-30 °C 1& maintained for 8 hour. The reaction mixture is poured into 300 ml water & layers are separated. Chloroform is evaporated 10-Methoxy-5H-dibenz [b, f] azepine-5-carbonyl chloride is isolated in methanol. Yield obtained is 110 gms (86%) of theoretical.
Step 2. Preparation of 10-Methoxy-5H-dibenz [b, fj azepine-5-carboxamide from 10- Methoxy-5H-dibenz [b, f] azepine-5-carbonyl chloride
100 gm of 10-Methoxy-5H-dibenz [b, f] azepine-5-carbonyl chloride is refluxed in 500 ml methanol. Dry ammonia is passed into the boiling solution for 2 hours. The methanol is distille water added -ar^-tøe-f-eaetiGr^ nixtw^s-^^ filtered. Yield of 10-Methoxy-5H-dibenz [b,f] azepine-5-carboxamide is 82 g. Step 3 Preparation of o-xcarbazepine -from 10-Methoxy-5H-dibenz (b, f) azepine 5- carboxamide
85 gm of 10-Methoxy-5H-dibenz [b, f] azepine-5 -carboxamide is dissolved in 425 ml of ethylene dichloride. To this 800 ml of 2N o-toluene sulfonic acid is added and heated to 75-80°C & maintained for bout 3 hours. It is then cooled to 20°C & maintained for about 1 hour. The product oxcarbazepine is separated by filtration. This is then purified in acetone-water to yield 55 gms of pure oxcarbazepine.
Example 2
Step 1. Preparation of 10-Methoxy-5H-dibenz [b, f] azepine-5-carbonyl chloride
100 gms of 10 -Methoxy iminostilbine is dissolved in 300 ml chloroform & cooled to 0°C. 65 gms of Bis (trichloro methyl) carbonate (BTC) is added to the solution followed by the addition of 54 gms of Dimethyl aniline in 100 ml chloroform over a period of 4 hours maintaining the temperature-0-5°C. The temperature is then maintained 0-10°C & maintained for 2 hours. The reaction mixture is poured into 300 ml water & layers are separated. Chloroform is evaporated & product is isolated in methanol. Yield obtained is 104 gms (82% of theoretical).
Example 3
Step 1. Preparation of 10-Methoxy-5H-dibenz [b,f] azepine-5-carbonyl chloride
100 gms of 10-Methoxy iminostilbene is dissolved in 300 ml chloroform & cooled to 0°C and 45 gms Bis (trichloro methyl) carbonate (BTC) is added followed by he addition of 45 gms of TEA in 100 ml chloroform over a period of 8 hours maintaining the temperature at 0~5°C. -The temperature4s then- increased to 25-30°C &-maintained for 2 hours. The reaction mixture is poured into 300 ml water layers are separated. Chloroform is evaporated & product is isolated in methanol. Yield obtained is 100 gms (80% of theoretical):
The present invention obviates the use of phosgene gas in the preparation of 10- methoxy^-dibenz[b,f]azepine-£ carbonyl chloride from 10~methoxy-5H- dibe φ,f]azepine (10-methgxy iminostilbene). Further the invention provide a process for the conversion of the intermediate 10-methoxy-5H-dibenz[b,f]azepine-5- carboxamiϋe to 10-oxo-10,11-dihydro-5H-dibenz [b,f] azepine-5-carboxamide (oxcarbazepine) without the use harsh conditions and strong mineral acids thereby obtaining high quality oxcarbazepine in a cost effective manner from easily available raw materials.

Claims

1. A novel process for preparation of 10-oxo-IO, 11-dihydro-5H-dibenz [b,f] azepine-5-carboxamide (oxcarbazepine) via intermediate 10-methoxy-5H- dibenz[b,f]azepine-5-carbonyl chloride, comprising the following steps: a) Preparation of an intermediate 10-methoxy-5H-dibenz[b,f] azepine-5- carbonyl chloride, from 10-methoxyiminostillbene using bis (trichloromethyl) carbonate (BTC) triphosgene with organic base / organic solvent b) Conversion of above intermediate to 10-methoxy-5H-dibenz[b,f] azepine-5- carboxamide using ammonia and with suitable solvent. c) Formation of oxcarbazepine from step (b) using Lewis acid in an appropriate organic solvent at a suitable temperature between 25- 80°C. preferably at 50 to 70 °C, d) Isolation using organic solvent,
2. A novel process as claimed in claim 1 , wherein at step (a) organic base is slowly added to the-sσlutioni r a period of 3-24 hrs, maintaining a temperature at 10°C, after completion of reaction, mixture is allowed to rise to room temperature, followed by separation of organic layer, and distilled to- get crude intermediate, purified using organic solvent.
3. A novel process as claimed in claim 1 & 2, wherein the ammonia gas is purged till the reaction completion, distilled the solvent, added water, followed by cooling at room temperature to isolate intermediate,
4. A novel process as claimed in the above claims, wherein the solvent selected is from chlorinated aliphatic hydrocarbons/aromatic hydrocarbons or aprotic solvent in the preparation of carbonyl chloride,
5. A novel process as claimed in claim 4, wherein chlorinated aliphatic solvents are such as- methylene- dichloride, - chloroform; ethyteήe dichrόrfde, ,T,1 ,- trichioroethaήe, trichloroethylene etc.
6. A novel process as .claimed in claim 4, wherein the solvent aromatic hydrocarbons ;are~sele~cted from toluene," xylehe, chlorob'enzene,- etc.
7. A novel process as claimed in claim 4, wherein the aprotic solvents are selected from Dimethyl formamide, Dimethyl acetamide, N-methyl pyrrolidine and acetonitrile.
8. A novel process as claimed in claim 1 & 2 wherein the organic base is selected from aliphatic / aromatic tertiary amines.
9. A novel process as claimed in above claims, wherein the molar ratio of 10- methoxy iminostilbene to BTC is 1:0.34 - 0.5, and the molar ratio with base is 1:1-1.5.
10. A novel process as claimed in claim 9, wherein the solvent selected from acetone, methyl cellulose, methanol, ethanol, isopropyl alcohol, dimethylforamamide etc.
11. A novel process as claimed in claim , wherein the Lewis acid is selected from p-toluene sulfonic acid, cationic resins etc.
12. A novel process for preparing 10-oxo-10,11-dihydro-5H-dibenz [b,f]azeρine-5- carboxamide (oxcarbazepine) via intermediate 10-methoxy-5H-dibenz[b,fjazepine-5-carbony! chloride substantially therein described with reference to foregoing examples.
PCT/IN2004/000322 2003-10-20 2004-10-15 NOVEL PROCESS FOR PREPARATION OF 10-OXO-10, 11-DIHYDRO-5H-DIBENZ [b,f]AZEPINE-5-CARBOXAMIDE (OXCARBAZEPINE) VIA INTERMEDIATE, 10-METHOXY-5H-DIBENZ[b,f] AZEPINE-5-CARBONYLCHLORIDE WO2005066133A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP04820974A EP1678140A2 (en) 2003-10-20 2004-10-15 Novel process for preparation of 10-oxo-10, 11-dihydro-5h-dibenz [b,f]azepine-5-carboxamide (oxcarbazepine) via intermediate, 10-methoxy-5h-dibenz [b,f] azepine-5-carbonylchloride
US10/576,546 US20070032647A1 (en) 2004-10-15 2004-10-15 Novel process for preparation of 10-oxo-10, 11-dihydro-5h-dibenz [b,f] azepine-5-carbox- amide (oxcarbazepine) via intermediate, 10-methoxy-5h-debenz[b,f] azepine-5-carbonyl- chloride

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1108/MUM/2003 2003-10-20
IN1108MU2003 2003-10-20

Publications (2)

Publication Number Publication Date
WO2005066133A2 true WO2005066133A2 (en) 2005-07-21
WO2005066133A3 WO2005066133A3 (en) 2005-10-06

Family

ID=34746667

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2004/000322 WO2005066133A2 (en) 2003-10-20 2004-10-15 NOVEL PROCESS FOR PREPARATION OF 10-OXO-10, 11-DIHYDRO-5H-DIBENZ [b,f]AZEPINE-5-CARBOXAMIDE (OXCARBAZEPINE) VIA INTERMEDIATE, 10-METHOXY-5H-DIBENZ[b,f] AZEPINE-5-CARBONYLCHLORIDE

Country Status (2)

Country Link
EP (1) EP1678140A2 (en)
WO (1) WO2005066133A2 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7125987B2 (en) 2004-06-18 2006-10-24 Apotex Pharmachem Inc. Process for the preparation of oxcarbazepine and related intermediates
WO2013008194A2 (en) 2011-07-13 2013-01-17 Ranbaxy Laboratories Limited Process for the preparation and purification of eslicarbazepine acetate and intermediates thereof
WO2014049550A1 (en) 2012-09-26 2014-04-03 Ranbaxy Laboratories Limited Process for the preparation of oxcarbazepine and its use as intermediate in the preparation of eslicarbazepine acetate
CN115650918A (en) * 2022-11-23 2023-01-31 浙江华洋药业有限公司 Preparation process of high-purity low-impurity 10-methoxyiminostilbene

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2011087A1 (en) * 1969-03-10 1970-09-24 J.R. Geigy AG, Basel (Schweiz) Process for the preparation of a new azepine derivative s
US5808058A (en) * 1995-01-13 1998-09-15 Trifarma S.R.L. Process for the preparation of 10-OXO-10, 11-dihydro-5H-dibenz (b,f) azepin-5-carboxamide

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT63389A (en) * 1991-12-27 1993-08-30 Alkaloida Vegyeszeti Gyar Improved process for producing 5-carbamoyl-10-oxo-10,11-dihydro-5h-dibenz/b,f/azepine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2011087A1 (en) * 1969-03-10 1970-09-24 J.R. Geigy AG, Basel (Schweiz) Process for the preparation of a new azepine derivative s
US5808058A (en) * 1995-01-13 1998-09-15 Trifarma S.R.L. Process for the preparation of 10-OXO-10, 11-dihydro-5H-dibenz (b,f) azepin-5-carboxamide

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE CA [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; HAASZ, FERENC ET AL: "Improved process for producing 5-carbamoyl-10-oxo-10,11-dihydro-5H- dibenz[b,f]azepine" XP002334714 retrieved from STN Database accession no. 1994:164010 & HU 63 389 A2 (ALKALOIDA VEGYESZETI GYAR, HUNG.) 30 August 1993 (1993-08-30) *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7125987B2 (en) 2004-06-18 2006-10-24 Apotex Pharmachem Inc. Process for the preparation of oxcarbazepine and related intermediates
WO2013008194A2 (en) 2011-07-13 2013-01-17 Ranbaxy Laboratories Limited Process for the preparation and purification of eslicarbazepine acetate and intermediates thereof
WO2014049550A1 (en) 2012-09-26 2014-04-03 Ranbaxy Laboratories Limited Process for the preparation of oxcarbazepine and its use as intermediate in the preparation of eslicarbazepine acetate
CN115650918A (en) * 2022-11-23 2023-01-31 浙江华洋药业有限公司 Preparation process of high-purity low-impurity 10-methoxyiminostilbene

Also Published As

Publication number Publication date
WO2005066133A3 (en) 2005-10-06
EP1678140A2 (en) 2006-07-12

Similar Documents

Publication Publication Date Title
EP0847390B1 (en) A PROCESS FOR THE PREPARATION OF 10-OXO-10,11-DIHYDRO-5H-DIBENZ(b,f)AZEPIN-5-CARBOXAMIDE
WO2012081035A2 (en) A process for preparation of praziquantel
CA2407173C (en) Process for the preparation of 10-methoxycarbamazepine
EP1678140A2 (en) Novel process for preparation of 10-oxo-10, 11-dihydro-5h-dibenz [b,f]azepine-5-carboxamide (oxcarbazepine) via intermediate, 10-methoxy-5h-dibenz [b,f] azepine-5-carbonylchloride
US7125987B2 (en) Process for the preparation of oxcarbazepine and related intermediates
US8476426B2 (en) Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
US20070032647A1 (en) Novel process for preparation of 10-oxo-10, 11-dihydro-5h-dibenz [b,f] azepine-5-carbox- amide (oxcarbazepine) via intermediate, 10-methoxy-5h-debenz[b,f] azepine-5-carbonyl- chloride
US7459553B2 (en) Process for the preparation of carboxamide compounds
EP1758867B1 (en) Process for preparing oxcarbazepine
WO2007141798A1 (en) Process for producing oxcarbazepine via an 11-alkoxy-10-halo-dihydroiminostilbene intermediate
KR101576620B1 (en) A new process for the preparation of 3-amino-9,13b-dihydro-1H-dibenz [c,f] imidazo[1,5-a]azepine bromic acid salt
US7091339B2 (en) Method of preparing a 5H-dibenz(b,f)azepine-5-carboxamide
WO2005118550A1 (en) A process for the preparation of iminostilbene derivatives
KR101637177B1 (en) Process for preparing 8-hydroxyclomipramine or its pharmaceutically acceptable salt
JP2007528385A6 (en) Method for producing oxcarbazepine
US8530647B2 (en) Process for the preparation of oxcarbazepine
US6245908B1 (en) Process for preparing carbamazepine from iminostilbene
KR100909295B1 (en) Method for preparing 6-aminomethyl-6,11-dihydro-5H-dibenz [e] ezepine
EP1026158B1 (en) Process for the preparation of 5-carbamoyl-5H-dibenz(b,f)azepine
EP1302464A1 (en) Process for preparation of 10-methoxycarbamazepine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004820974

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10576546

Country of ref document: US

Ref document number: 2007032647

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2004820974

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 10576546

Country of ref document: US